Africa Healthcare Network has received a USD 20mn debt and equity investment from Africa50, AfricInvest, Japan’s Ohara Pharmaceutical and others to expand into other African countries.
AHN will use the funding to reach its goal of having over a hundred dialysis centres by 2025 from its current 45.
The equity portion of the investment was led by Africa50, while AfricInvest provided debt financing through its Transform Health Fund.
CrossBoundary advised AHN on the deal.
Ohara Pharmaceutical’s main specialism is orphan drug discovery and generic drug development and manufacturing. The company is now providing total healthcare solutions with prevention diagnosis and aftercare to enhance a patient’s quality of life.